Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Mateos MV, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E, Delforge M, Ocio E, Katodritou E, Gay F, Larocca A, Leleu X, Otero PR, Schjesvold F, Cavo M, Dimopoulos MA.
Mateos MV, et al. Among authors: kastritis e.
Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284694. Online ahead of print.
Haematologica. 2024.
PMID: 38385280
Free article.